1. Background
Mutations in the fragile X mental retardation 1 gene are the most common single genetic cause of autism-spectrum disorders. A number of individuals with Fragile X syndrome (FXS) have been shown to have some symptoms of autism such as hand flapping, poor eye contact, hand biting, perseveration in speech, and tactile defensiveness (1).The alleles are categorized according to the CGG repeat numbers as normal, intermediate (IM), premutation (PM), and full mutation. The normal or common size allele consists of 5 - 39 CGG repeats, intermediate alleles have approximately 40 - 54 CGG repeats, premutation alleles range from 55 - 200 repeats, and the size range of full mutation alleles is > 200 up to several thousand CGG repeats (2).
There is no linear correlation between the number of CGG repeats and clinical manifestations (3). In males with the full mutation, transcription is blocked due to methylation resulting gene silencing and usually affected. Approximately half of females with the full mutation have borderline IQs or are mentally retarded. Those with m typical IQ may have learning deficit or emotional symptoms (4). Formerly PM carriers, supposed to be clinically unaffected, are now known to be at increased risk of premature ovarian failure (POF) (OMIM #311360), Fragile X-associated tremor/ataxia syndrome (FXTAS) (OMIM #300623), autism (OMIM #209850), emotional problems, late-onset neurodegenerative disorder, and neurocognitive deficits (3). The basis for the variable clinical presentation among individuals with IM and PM alleles is not exactly known. FMRP levels have commonly been thought to be normal for small alleles (< 100 repeats) and moderately decreased for larger PM alleles (5). Therefore, at the level of FMRP production, the model and clinical presentation are qualitatively consistent. While FMRP levels appear to be low in the upper PM range, due to a defect in the translation efficiency of the gene, the mRNA levels are actually high (6).
It is hypothesized that the presence of elevated levels of mRNA has a toxic “gain-of-function” effect as it has been proposed for the etiology of myotonic dystrophy (7). The presence of a pathology involving the PM allele would be of great importance given the high prevalence of these alleles in the general population. The lower limit of the premutation range remains imprecise.
The clinical manifestations of PM alleles POF, autism, and FXTAS may result from this “mRNA poisoning” effect (3). It has been proposed that expansion in CGG repeat number results in elevated levels of transcripts, which interfere with the binding of several RNA-processing factors, generating novel forms of mRNA, and thus leading to functional changes in the corresponding proteins and progressive cell death (8) This mechanism has been supported by both and premutation mouse models (9, 10).
The impact of IM alleles (also known as ‘grey zone’ alleles) of CGG number is much less clinically understood. There are various definitions of intermediate alleles. Alleles in this range can be considered normal in the sense that such alleles have not been observed to expand to a full mutation in one generation although initially minor increases in repeat number can be observed in these alleles. A number of recent studies have demonstrated the elevation of mRNA levels in IM and PM CGG allele carriers with a lower threshold at 40 repeats (11). On this base, IM alleles have been categorized as 40 - 54 repeats throughout this paper. The frequency of IM alleles in various population samples is nearly 2% - 3% (2, 12). Furthermore, intermediate alleles have recently been considered to be associated with specific clinical phenotypes.
The first report of a clinical phenotype associated with intermediate alleles was “learning difficulties” in special educational needs children (2, 12-14). Two studies reported a significant increase of intermediate alleles in POF populations (15, 16). Previously, we showed that intermediate alleles are associated with parkinsonism (11), and also reported that epigenetic components might be involved in the toxicity of excessive mRNA in small size alleles (17). Our preliminary results showed that PM and IM alleles may be attributed to neurodevelopmental conditions (17). Therefore, current literature suggests autism and small size alleles might overlap. In this study, we screened DNA samples for the presence of IM or PM alleles in 96 autism patients and found significant excess of both alleles in comparison with control subjects.
2. Methods
This study was approved by the Tabriz University of Medical Sciences ethics committee. All patients and normal controls were of the same ethnicity, white Caucasians of Asian origin.
2.1. Patient Subjects
This study was designed to establish the frequencies of intermediate and premutation alleles among 96 males with Autistic disorder who were diagnosed by pediatric neurologists or psychiatrists and 132 male control subjects. Patients were employed based on clinical phenotype of DSM-IV criteria. The age of the patients was ranging from 2 years to 20 years, and that of the control subjects from 6 - 18 years. There were no significant differences in age and ethnicity of the groups. All subjects participated in the study with informed consent, which has been approved by the ethical committee.
2.2. Molecular Analysis
Genomic DNA was extracted from whole blood based on salting out method (17). Pureness and amount of the isolated DNA samples were measured by spectrophotometry. Polymerase chain reaction (PCR) was performed using previously published protocol (18). The PCR amplification was carried out in a final reaction volume of 25 μL containing ~100 ng of genomic DNA, 4 pmol/l of each primer, 2.5 μL 10x PCR buffer, 0.25 mM of each dNTP, 1.5 mM MgCl2, 2 units SmarTaq DNA polymerase (Cinnagen, Iran), and 2.5 μL of Q solution.
The PCR cycling profile was as follows: initial denaturation at 98°C for 5 minutes; 35 cycles at 98°C for 45 seconds, 68°C for 30 seconds, 72°C for 1 minutes, and a final extension at 72°C for 10 minutes using the Gene Amp@ PCR System 9700 (Applied Biosystem). PCR products were visualized by 3% agarose gel electrophoresis and measured using standards and controls of 30- and 75-repeat lengths beforehand defined by sequencing method. In order to more accurately determine the CGG repeat size of samples were determined as IM or PM alleles in agarose electrophoresis were sequenced for CGG repeat tracts (Macro gene company, Seoul, South Korea). PCR products were purified and sequenced using the BigDye ve3.1 Terminator Cycle Sequencing kit (Applied Biosystems). Samples with no band in PCR were assumed as full mutation alleles and excluded from our study to be examined using Southern blot.
3. Results
All statistical analyses were carried out using the STATA statistical package and -value of 0.05 or below has been taken to be statistically significant. In this study, IM and PM alleles have been classified as 40 - 54 and 55 - 200 repeats, respectively. Three mutated, five intermediate, and four premutation carriers were identified among Autistic patients. In normal controls no intermediate, no full mutation alleles, and one premutation carrier were observed, representing a noteworthy excess in small size FMR1 allele carriers.
First, we compared the distribution of alleles using Fisher’s exact and chi-squared tests and demonstrated a highly significant increase in the proportions of small CGG FMR1 alleles (IM and PM alleles) in Autism subjects compared with male control. Ten intermediate and premutation carriers (CGG repeat numbers equal 44, 48, 51, 51, 58, 75, 90, 95 and103) were found among 96 Autism patients, compared with one in 168 normal controls, representing a significant excess (two-sided Fisher’s exact test, -value = 0.0006 and two-side chi-squared P value < 0.0003) ( Table 1).
Table 1.Comparison of Frequencies of CGG Allele Categories Between Autism Patients and Control Group (Normal: 0 - 40 Repeats; Intermediate: 40 - 60 Repeats; Premutation 61 - 200 Repeats)a
| Sample | CGG Categories | Total | |
|---|---|---|---|
| 0 - 39 | 40 - 54 and 54 - 200 | ||
| Control | 167 | 1 | 168 |
| Autism | 87 | 9 | 96 |
| Total | 254 | 10 | 264 |
aFisher’s two-sided -value = 0.0006, Chi-square two-sided -value = 0.0003.
Using the same method, we also demonstrated a significant increase in the proportion of intermediate alleles in Autism subjects compared with male controls (two-sided Fisher’s exact test, -value = 0.006 and two-side chi-squared -value = 0.002) (Table 2).
Table 2.Comparison of Frequencies of CGG Allele Categories Between AD and Control Group (Normal: 0 - 40 Repeats; Intermediate: 40 - 60 Repeats)a
| Sample | CGG Categories | Total | |
|---|---|---|---|
| 0-39 | 40-54 | ||
| Control | 168 | 0 | 168 |
| Autism | 91 | 5 | 96 |
| Total | 259 | 5 | 264 |
aFisher’s two-sided P value = 0.006, Chi-square two-sided -value = 0.002.
Three patients, in whom DNA was not amplified, were assumed to be fully mutated. Their agarose gel electrophoresis results displayed full mutation by lack of amplification, because of large expansions. No full mutation was found in the control population.
4. Discussion
During last decades, the established molecular model offering that neuropsychological abnormalities in Fragile X result from significant loss of FMRP production has been revised. There are many reports that PM CGG alleles have clinically effects, despite normal FMRP protein. In this study, it was hypothesized that IM-size alleles may play some role in the cause of autism disorders. This was based on the earlier finding (11) that the level of mRNA in individuals with intermediate CGG repeat size alleles is similar to that associated with PM alleles which are known to be associated with some neurodevelopmental conditions and late onset tremor ataxia (FXTAS) (19). Autism is currently considered to be a multifactorial disorder that involves a strong genetic influence (20). Identification of molecular factors that account for the development of autism is currently an area of extensive research. It has been shown as a part of the behavioral phenotype in several genetic disorders, including FXS, phenylketonuria (PKU), tuberous sclerosis, Rett syndrome, and duplications in chromosome 15q (21-23).
There is a clear correlation between FMRP concentration and mean scores of childhood autism rating scale (CARS); the lower FMRP concentration, the lower CARS in autistic child. It has been reported that individuals with FXS autism had a lower IQ than non-autistic individuals with FXS alone (24). So far, clinical involvement of intermediate size alleles has been proved in POF, but not much evidence has been presented for neurodegenerative and neurodevelopmental disorders. The association of small CGG repeat expansion FMR1 alleles with parkinsonism and autistic phenotype in Australian population has been presented (17, 25, 26). We continued our research in other ethnic groups in order to confirm pervious findings. Therefore, FMR1 intermediate alleles among 96 autistic males were screened and IM-size alleles in five autistic males were found, with prevalence close to 5%. The role of IM alleles in autistic disorder and any behavioral and/or cognitive phenotypes is controversial. Several studies report an association of IM alleles with an increased risk of autism-spectrum disorders (5, 17). Their findings revealed a high occurrence of IM alleles that has also been related to an increased risk of behavioral phenotypes (1). Other studies failed to replicate these findings. In Spain and Japan, the frequency of IM alleles were screened among autistic patients and showed no association between IM alleles and increased risk of Autistic disorder (27, 28). This study was planned to obtain additional data and may help to resolve this controversy. Our data from the samples of males with autism suggest that intermediate alleles may play a part in the etiology of some forms of idiopathic autism and recommended our pervious published results (25). Considering that one in 30 - 40 individuals in the general population is a carrier of an intermediate size allele, the potential significance of these findings is obvious, and further screening of well-powered cohorts of patients with autism, as well as detailed neurological examinations is warranted (17).
Despite the small sample size in this study, our findings add weight to the suggestion that IM alleles of CGG repeats have specific clinical manifestations and should be considered as a risk factor for Autistic disorder. However, these results need to be duplicated in other independent samples and larger populations. More studies are required with large number of case and control populations from different ethnic groups to prove that intermediate alleles can contribute to the etiology of neurodevelopmental and neurodegenerative disorders. If these recent results can be replicated in other independent samples using a larger population-based control sample, it will open a new area of examination into molecular patho-mechanisms of the smallest CGG expansions and their impact on clinical phenotype.
